Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients

Coronary Artery Disease

Volumn 23, Issue 2, 2012, Pages 85-90

  Yoon, Se Jung ^a   Park, Sungha ^b   Park, Chanmi ^c   Chang, Woochul ^c   Cho, Deok Kyu ^b   Ko, Young Guk ^b   Choi, Donghoon ^b   Kwon, Hyuck Moon ^b   Jang, Yangsoo ^b   Chung, Namsik ^b  

^a National Health Insurance Corporation   (South Korea)

^b Division of Cardiology   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Advanced glycation end product; Aortic stiffness; Hypertension; Soluble receptor for advanced glycation end product

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN;

ARTERIAL STIFFNESS; AUGMENTATION INDEX; BLOOD SAMPLING; CAROTID ARTERY; DIABETIC PATIENT; FEMALE; FEMORAL ARTERY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; REVIEW;

BIOLOGICAL MARKERS; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX; VASCULAR STIFFNESS;

EID: 84857239314     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32834f114e     Document Type: Review

References (35)

1. Kim JB, Song BW, Park S, Hwang KC, Cha BS, Jang Y, et al. Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model. Korean Circ J 2010; 40:520-526.
2. Rojasa A, Morales MA. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci 2004; 76:715-730. (Pubitemid 39576147)
3. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007; 23:368-371. (Pubitemid 47091239)
4. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23:1725-1729. (Pubitemid 41233433)
5. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25:1032-1037. (Pubitemid 40627851)
6. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49:2756-2762.
7. Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease. The next C-reactive protein? Arterioscler Thromb Vasc Biol 2005; 25: 879-882. (Pubitemid 40637200)
8. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2008; 204:288-292.
9. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998; 4:1025-1031. (Pubitemid 28417334)
10. Humpert PM, Kopf S, Djuric Z, Wendt T, Morcos M, Nawroth PP, et al. Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care 2006; 29:1111-1113. (Pubitemid 44115254)
11. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6:9.
12. Koyama Y, Takeishi Y, Niizeki T, Suzuki S, Kitahara T, Sasaki T, et al. Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 2008; 14:133-139. (Pubitemid 351312887)
13. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007; 13:185-189. (Pubitemid 46944961)
14. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25:2587-2593. (Pubitemid 43732283)
15. Nagano M, Nakamura M, Sato K, Tanaka F, Segawa T, Hiramori K. Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population. Atherosclerosis 2005; 180:189-195.
16. Munakata M, Ito N, Nunokawa T, Yoshinaga K. Utility of automated brachial ankle pulse wave velocity measurements in hypertensive patients. Am J Hypertens 2003; 16:653-657. (Pubitemid 36900588)
17. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11:2279-2299. (Pubitemid 40872698)
18. Park S, Yoon SJ, Tae HJ, Shim CY. RAGE and cardiovascular disease. Front Biosci 2011; 16:486-497.
19. Yoon SJ, Yoon YW, Lee BK, Kwon HM, Hwang KC, Kim M, et al. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med 2009; 41:802-811.
20. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor alpha through nuclear factor-kappa B, and by 17 beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 275:25781-25790.
21. Yamagishi S, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol 2007; 27:e32. (Pubitemid 46809443)
22. Schlueter C, Hanke S, Flohr AM, Rogalla P, Bullerdiek J. Tissue specific expression patterns of RAGE receptor and its soluble forms - a result of regulated alternative splicing? Biochem Biophys Acta. 2003; 1630:1-6 (Pubitemid 37297971)
23. Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, Matsui T, Jinnouchi Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005; 70:137-141. (Pubitemid 41586467)
24. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26:2716-2723.
25. Mattace-Raso FU, van der Cammen TJ, van der Meer IM, Schalekamp MA, Asmar R, Hofman A, et al. C-reactive protein and arterial stiffness in older adults: the Rotterdam Study. Atherosclerosis 2004; 176:111-116. (Pubitemid 39078652)
26. Wang YX, Fitch RM. Vascular stiffness: measurements, mechanisms and implications. Curr Vasc Pharmacol 2004; 2:379-384. (Pubitemid 39200188)
27. Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 2003; 12:181-187. (Pubitemid 36288319)
28. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005; 28:2716-2721. (Pubitemid 43951165)
29. Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, et al. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 2009; 132:96-101.
30. Thomas MC, Söderlund J, Lehto M, Mäkinen VP, Moran JL, Cooper ME, et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of allcause and cardiovascular mortality in type 1 diabetes. Diabetologia 2011; 54:2669-2677.
31. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, et al. N(epsilon) (carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 29:31740-31749.
32. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13:1971-1978.
33. Bucciarelli LG,Wendt T, QuW, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106:2827-2835. (Pubitemid 35396983)
34. Lin L, Park S, Lakatta EG. RAGE signaling in inflammation and arterial aging. Front Biosci 2009; 14:1403-1413.
35. Soro-Paavonen A,Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57:2461-2469.